Novapeutics

Novapeutics is a biopharmaceutical company, the company is a spinoff from the University of Pennsylvania that aims to develop oral curative therapeutic for reversing the course of diabetes by regenerating insulin-producing beta cells. Novapeutics utilizes a patent pending approach to develop treatments for type 2 diabetes using menin inhibitors.

The company's approach uses small molecule therapeutics to disrupt menin and mixed lineage leukemia (MLL) proteins, which enhances endogenous beta cell regeneration in diabetes patients. The company has currently identified promising novel menin inhibitors as its drug leads, with the support of the SBIR funding from NIH/NIDDK.